Bone Metabolism Markers
Bone Metabolism Markers - Related Videos
07:45
Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis
0 Views •
Cited by 274 •
2015
Metabolic reprogramming is a characteristic and prerequisite for M1 and M2 macrophage polarization. This manuscript describes an assay for the measurement of fundamental parameters of glycolysis and mitochondrial function in mouse bone marrow-derived macrophages. This tool can be applied to investigate how particular factors affect the macrophage’s metabolism and phenotype.
05:41
Metabolic Profile Analysis of Zebrafish Embryos
0 Views •
Cited by 42 •
2013
Zebrafish represent a powerful vertebrate model that has been under-utilised for metabolic studies. Here we describe a rapid way to measure the in vivo metabolic profile of developing zebrafish that allows the comparison of different mitochondrial function parameters between genetically or pharmacologically manipulated embryos, thereby increasing the applicability of this organism.
08:49
Models of Bone Metastasis
0 Views •
Cited by 115 •
2012
Animal models are frequently utilized to study cancer metastasis to bone. In this protocol we will describe two common methods of tumor inoculation for bone metastasis studies and briefly describe some of the analyses utilized to monitor and quantify these models.
10:19
An Introduction to Cell Metabolism
0 Views •
2023
In cells, critical molecules are either built by joining together individual units like amino acids or nucleotides, or broken down into smaller components. Respectively, the reactions responsible for this are referred to as anabolic and catabolic. These reactions require or produce energy typically in the form of a “high-energy” molecule called ATP. Together, these processes make up “Cell Metabolism,” and are hallmarks of healthy, living cells.JoVE’s introduction to cell metabolism briefly...
11:39
Identifying Cell Surface Markers of Primary Neural Stem and Progenitor Cells by Metabolic Labeling of Sialoglycan
0 Views •
Cited by 1 •
2019
Presented here is a protocol that combines an in vitro neural-endothelial co-culture system and metabolic incorporation of sialoglycan with bioorthogonal functional groups to expand primary neural stem and progenitor cells and label their surface sialoglycoproteins for imaging or mass-spectrometry analysis of cell surface markers.
FAQs
Bone mineral density testing reflects accumulated mineral content, whereas these markers reflect current activity of bone-remodeling cells. Formation and resorption measurements can therefore show changes in skeletal turnover that may occur before a measurable structural change in density. This makes them useful complementary measures when clinicians evaluate skeletal health or treatment effectiveness.
Formation markers reflect activity of osteoblasts, the cells responsible for building bone. Bone-specific alkaline phosphatase and osteocalcin are examples of markers associated with this process. Measuring them gives clinicians information about the formation side of remodeling, helping distinguish changes in bone-building activity from changes primarily related to matrix degradation.
CTX is a collagen fragment released when osteoclasts degrade bone matrix. Because it arises from the resorption process, its measurement provides a biochemical indication of osteoclast-related activity rather than accumulated bone mineral. CTX can be assessed in blood or urine, allowing resorption-related changes to be evaluated as part of skeletal assessment.
Clinical evaluation uses biochemical measurements of formation or resorption markers, depending on the remodeling process of interest. Bone-specific alkaline phosphatase and osteocalcin represent formation-related activity, while CTX represents matrix degradation. CTX measurements may use blood or urine, and the resulting data complement structural assessment with bone mineral density testing.
Clinicians can measure these markers while evaluating responses to antiresorptive or bone-forming therapies. Because the measurements reflect remodeling activity, they may reveal changes in treatment effectiveness earlier than structural measurements. This provides a dynamic monitoring approach that complements bone mineral density and helps assess whether skeletal activity is changing during therapy.
In medicine, bone metabolism markers support the evaluation of metabolic bone disorders and broader assessment of skeletal health. They also help interpret treatment-related changes when bone mineral density alone provides an accumulated structural measure. Using both types of information allows clinicians to consider present remodeling activity alongside the mineral content established over time.